Orexigen's Contrave lowers heart disease risk By: MarketMinute.com Stock News March 03, 2015 at 12:33 PM EST Orexigen Therapeutics Inc.'s (Nasdaq: OREX) obesity treatment Contrave reduced the risk of heart disease by almost half. The stock price leaped $2.79 to $8.58.